Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study

PLoS ONE(2022)10.1371/journal.pone.0263911Source: DataRank Database

The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study is a research paper published in PLoS ONE (2022). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.41)OA: goldTopics (54)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Chung Yin Kong ORCID,Michael K. Gould ORCID,Minal Kale ORCID,Rajwanth Veluswamy ORCID,Cardinale B. Smith ORCID

Live enrichment

PubMed:36378625 PMC:PMC9665372 OpenAlex:https://openalex.org/W4309070560

National Cancer Institute

Grant: T32CA225617

National Cancer Institute

Grant: R01CA202956

NCI NIH HHS

Grant: T32 CA229110

National Institutes of Health

Grant: 5R01CA202956-03

Optimizing Treatment of Lung Cancer Patients with Comorbidities

National Institutes of Health

Grant: 5T32CA225617-03

Training Program in Cancer Prevention and Control for Priority Populations

FWCI

0.41

Citation Percentile

0.6%

Citation Trend

2023

2026

goldLicense: cc-by

journalhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0263911&type=printable

publisherhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0263911&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pone.0263911

journalhttps://doi.org/10.1371/journal.pone.0263911

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36378625

Fields of Study

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and MutationsGlobal Cancer Incidence and Screening03 medical and health sciences0302 clinical medicineMaleFemaleHumansAged, 80 and overCarcinoma, Non-Small-Cell LungLung NeoplasmsChemotherapy, AdjuvantComorbidityPulmonary Disease, Chronic ObstructiveNeoplasm StagingAntineoplastic Combined Chemotherapy Protocols

MeSH Terms

Aged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleNeoplasm StagingComorbidityChemotherapy, AdjuvantPulmonary Disease, Chronic Obstructive

Keywords

MedicineChemotherapyAdjuvant chemotherapyOncologyLung cancerCancerAdjuvantIntensive care medicineInternal medicineBioinformaticsBiologyBreast cancerMaleAged, 80 and overLung NeoplasmsScienceQRComorbidityPulmonary Disease, Chronic ObstructiveChemotherapy, AdjuvantCarcinoma, Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleResearch ArticleNeoplasm Staging

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being